Furthermore, Sorafenib displayed superior antitumor efficacy in FLT3-ITD acute myeloid leukemia patients [66], especially undergoing allogeneic hematopoietic stem-cell transplantation [67, 68]. The gene discussed is FLT3; the disease is acute myeloid leukemia.